Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: Clinical implications of recent studies

Research output: Contribution to journalReview article


Clinicians should consider using new mold-active azole drugs for prophylaxis instead of fluconazole in allogeneic hematopoietic stem cell transplant recipients that have high risks due to prolonged neutropenia and severe graft vs. host disease. More investigations are needed to support other preventive strategies that utilize diagnostic tests and aerosolized delivery of amphotericin B formulations.

Original languageEnglish (US)
Pages (from-to)409-414
Number of pages6
JournalCurrent opinion in infectious diseases
Issue number4
StatePublished - Aug 1 2008
Externally publishedYes



  • Invasive fungal infections
  • Prophylaxis
  • Transplantation

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this